Skip to main content
. 2013 Jan 29;2013:931972. doi: 10.1155/2013/931972

Table 2.

Response to sorafenib treatment in patients with advanced HCC according to the intention to treat analysis (ITT) and in patients treated for at least 3 months.

Response ITT, N (%) Evaluable pt.* N(%)
Complete response
Partial response 7 (9.3) 7 (21.9)
Stable disease 18 (24.0) 18 (56.2)
Progressive disease 8 (10.7) 8 (25)
Not assessable 1 (1.3) 1 (3)
Disease control rate 33.3% 78.1%

*Response evaluated in patients completing 3 months of sorafenib therapy.